健择治疗未分化甲状腺癌动物实验模型-第三军医大学学报.docVIP

健择治疗裸鼠未分化甲状腺癌的实验研究 陈磊1，张青云1，杨植，高建国1，郭风玲1，刘彦春1，陈序吾2 1.承德医学院附属医院外二科2.哈尔滨医科大学附属第一医院普外科 摘要 目的： 建立甲状腺未分化癌体内试验模型；检验健择对甲状腺未分化癌的治疗作用。 方法： 用人类未分化甲状腺癌细胞系（ARO）以及与之相对照的分化型甲状腺癌细胞系（乳头状癌NPA、滤泡状癌WRO）单细胞悬液裸鼠皮下注射的方法建立甲状腺癌异体移植模型。检测肿瘤细胞对健择以及合并放疗的敏感性。结果：比较健择治疗前后肿瘤体积有统计学意义，（P 0.01）（P 0.05）（P 0.01）（P 0.001）The in-vivo study in nude mice of Gemcitabine Against Poorly Differentiated Thyroid Carcinoma Cells Chen Lei, Zhang Qing-yun, Yang Zhi, et al. The 2nd Surgery of ChengDe Medical Univeersity. ChengDe, HeBei Province, China, 067000. Abstract Objective: To determine xenograft model with human thyroid cancer cell lines in nude mice is stable; To test gemcitabine and/or radiation are toxic to the xenograft tumors. Methods: Human thyroid cancer cell line ARO, WRO, and NPA are cultured respectively and was suspended to single cell line solution, which were injected underneath the nude mouse’s skin. Then gemcitabine and radiotherapy is given. An antitumor effect is expressed in terms of the variation of the tumor volume. Results: Anaplastic thyroid cancer cell line ARO is sensitive to Gemcitabine; Radiotherapy is no effect; Gemcitabine plus radiotherapy couldn’t enhance the therapy effect. Conclusion: Human thyroid cancer xenograft model can be established by injecting single cell line solution underneath nude mouse’s skin; Gemcitabine is effective to treat human undifferentiated thyroid cancer; According this test system, whether radiotherapy is added needs farther consideration. Key words: Gemcitabine; Anaplastic thyroid carcinoma; Radiotherapy; Chemotherapy; Nude mice 本实验旨在探讨以健择作为化疗药物对甲状腺未分化癌进行化疗及联合放疗的疗效，为甲状腺未分化癌的综合治疗寻找有效手段，为临床应用提供依据。 甲状腺未分化癌是高度恶性的内分泌肿瘤之一，无论治疗与否平均生存时间为4～10个月[1]。由于甲状腺未分化癌生长快，发生局部和远隔转移早。同时此类癌细胞不浓聚碘，对化疗和放疗不敏感，因此常用的根治性手术结合放射治疗及化疗很难控制病情进展。常用的化疗药物包括阿霉素和联合化疗方案，然而至今仍无治愈的相关报道。健择通用名称盐酸吉西他滨（Gemcitabine））））,为肿瘤细胞植入后治疗时仅用生理盐水（健择载体）。每组8～10只鼠（实验数据选取肿瘤体积符合实验要求的鼠7只）。 1.6、统计学方法：记录各组肿瘤体积用±s表示，各组内治疗前、后采用t检验，组间（健择组和健择+放疗组）采用重复测量F试验，由SPSS 13.0软件完成。 1.7、病理学检查：裸鼠CO2麻醉死亡后，切取食管、肺脏、肝脏